Bayer 20324 ON-TRK
ON-TRK: PrOspective Non-interventional study in patients with locally advanced or metastatic TRK fusion cancer treated with larotrectinib
AbbVie M19-037
A Phase 1, Multicenter, Open-Label Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Combination of ABBV-927 with ABBV-368, Budigalimab (ABBV-181) and/ or Chemotherapy in Subjects with Locally Advanced or Metastatic Solid Tumors
Seagen SGNLVA-005
Open-Label Phase 2 Study of Ladiratuzumab Vedotin (LV) for Unresectable Locally Advanced or Metastatic Solid Tumors
LabCorp PREFER
Prospective registry of advanced stage cancer (PREFER) patients to assess prevalence of actionable biomarkers and driver mutations using the OmniSeq test and creation of a biobank from community cancer clinics in the United States to address disparities in precision medicine
Natera 20-43-NCP Bespoke IO
BESPOKE Study of ctDNA Guided Immunotherapy (BESPOKE IO).
©2019 Fort Wayne Medical Oncology and Hematology. All Rights Reserved.